Avidity Biosciences Inc at Chardan Genetic Medicines Conference Transcript

Oct 03, 2023 / 01:00PM GMT
Keay Nakae - Chardan Capital Markets - Analyst

It's my pleasure to introduce our next guest from Avidity. Today, we have with us the Chief Medical Officer, Dr. Steve Hughes; the CFO, Mike MacLean; and a distinguished scientists and strategic leader, Dr. Art Levin. So welcome all of you. Thanks for being with us.

Questions and Answers:

Keay Nakae - Chardan Capital Markets - Analyst

Mike, maybe to start, can you provide a brief overview of the company and some of your key achievements in 2023 to date?

Mike MacLean - Avidity Biosciences, Inc. - Chief Financial and Business Officer

Yeah. First of all, Keay, thank you for hosting us here today. It's always great to come to this conference. So in terms of Avidity, I guess the best thing to describe where we are at this point in time is that we are executing on our strategy. We now have three clinical programs in process, all in neuromuscular space. And we're also expanding the pipeline both in neuromuscular and specifically in cardiovascular as we moved into 2024,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot